UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
Innate Immunity in NASH
Innate Immunity in NASH is a funding opportunity from UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, up to 473979, closing April 30, 2027.
Apr 30, 2027
(273d left)Overview
Nonalcoholic steatohepatitis (NASH), a cell death and inflammation-associated nonalcoholic fatty liver disease (NAFLD), is the leading cause of hepatocellular carcinoma (HCC) and end-stage liver failure worldwide. There is no effective therapeutic drug for NASH to date, highlighting an urgent need for the…